Johnson & Johnson Invests $1 Billion in Next-Gen Cell Therapy Manufacturing in Pennsylvania
This is part of J&J's $55B investment in US manufacturing over the next few years.
Manufacturing
Innovacell Seeks $92M in Tokyo IPO to Advance Stem Cell Therapy Development
The company is developing autologous cell therapies for fecal and urinary incontinence tied to weakened sphincter muscles.
Pluristyx and Solesis Release New 3D Stem Cell Transfection Kit to Improve Efficiency and Reduce Toxicity
A new kit aims to streamline 3D iPSC transfection, offering higher efficiency and lower cytotoxicity for researchers and developers.
GWOXI Files FDA Drug Master File for Adipose-Derived Stem Cell Bank
GwoXi’s FDA filing aims to support cell therapy and exosome developers with a standardized, traceable stem cell source.
Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation Technologies
The lipid microbubble platform aims to enhance cell therapy manufacturing, adapted from its clinically validated ultrasound imaging tech.
Lineage Cell Therapeutics Receives Gene-Edited Stem Cell Line for Immune System Compatibility Studies
Lineage will evaluate the new gene-edited iPSC line for immune compatibility and manufacturing potential before pursuing exclusive rights with Factor Bioscience.
Multiply Labs Nabs Partnership with AstraZeneca to Explore Robotic Automation in Cell Therapy Production
The collaboration will assess whether robotic automation can help scale up cell therapy manufacturing while maintaining GMP standards.
Cellares Teams Up with Stanford to Automate Gene-Edited Stem Cell Therapy Manufacturing
The partnership aims to streamline production and quality testing of gene-edited hematopoietic stem cell therapies for HIV and rare diseases.
Longeveron Nabs Patent for Stem Cell Testing Techniques in Japan
With the right secured for stem cell potency, Longeveron is continuing its path forward with clinical trials for several mesenchymal stem cell indications.
REPROCELL Launches StemEdit: AI-Designed Gene Editing System and iPSC Product Lines for Clinical Use
The new open source gene editing services are ready to help iPSC developers create off-the-shelf allogeneic cell therapies at scale.
